Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer
NCT ID: NCT06528483
Last Updated: 2024-07-30
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
NOT_YET_RECRUITING
Clinical Phase
PHASE2
Total Enrollment
63 participants
Study Classification
INTERVENTIONAL
Study Start Date
2024-12-02
Study Completion Date
2029-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Patients with MIBC N0/N1 unwilling or unfit for cystectomy will receive SG + Zimberelimab for 3 cycles of treatment prior of first radiological and TURB re-evaluation.
Patients with stable disease or downstaging will continue Zimberelimab up to 1 year. The goal of this trial is to demonstate that Sacituzumab Govitecan + Zimberelimab can avoid cistectomy and can prolong or avoid recurrence to metastatic disease in selected patients with muscle-invasive bladder cancer.
The primary endpoint of this trial is Event Free Survival that is defined as clinical evidence of new or progressing nodal or any distant metastatic disease, radical cystectomy, or death due to any cause from date of inclusion to the first documentation of a EFS event.
Patients with stable disease or downstaging will continue Zimberelimab up to 1 year. The goal of this trial is to demonstate that Sacituzumab Govitecan + Zimberelimab can avoid cistectomy and can prolong or avoid recurrence to metastatic disease in selected patients with muscle-invasive bladder cancer.
The primary endpoint of this trial is Event Free Survival that is defined as clinical evidence of new or progressing nodal or any distant metastatic disease, radical cystectomy, or death due to any cause from date of inclusion to the first documentation of a EFS event.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer
NCT06133517
Urothelial Bladder Carcinoma
RECRUITING
PHASE2
Pembrolizumab-Sacituzumab Govitecan Combination to Treat High-risk, Localized Bladder Cancer
NCT05535218
Muscle-invasive Urothelial Carcinoma of the Bladder
ACTIVE_NOT_RECRUITING
PHASE2
Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer
NCT05581589
Muscle Invasive Bladder Carcinoma
Stage II Bladder Cancer AJCC v8
Stage IIIA Bladder Cancer AJCC v8
RECRUITING
PHASE2
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
NCT03547973
Metastatic Urothelial Cancer
RECRUITING
PHASE2
Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer
NCT05226117
Urothelial Carcinoma
RECRUITING
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is an open-label, multi-center, single-group, phase 2 study. Patients with MIBC N0/N1 unwilling or unfit for cystectomy will receive SG + Zimberelimab for 3 cycles of treatment prior of first radiological and TURB re-evaluation.
Approximately 63 patients will be enrolled and assigned to study intervention. At screening, a tumor specimen from TURBT or biopsy done as early as 90 days prior to enrollment will be submitted for central pathology review. All participants will undergo baseline screening imaging (CT or MRI of the chest, abdomen, pelvis) for clinical staging.
Eligible participants will be allocated to study intervention which consist in SG + Zimberelimab for 3 cycles followed by Zimberelimab for 13 cycles in patients who achieve CR/PR/SD at tumor evaluation.
The planned total duration of treatment is approximately 1 year, 3 cycles of SG and 16 cycles of Zimberelimab.
Treatment will be discontinued if the participant experiences unacceptable AE(s), intercurrent illness that prevents further administration of treatment, the investigator's decision to withdraw the participant, the participant withdraws consent, pregnancy of the participant, noncompliance with study intervention or procedure requirements, or the maximum number of cycles has been received for each treatment component individually.
Participants will complete 3 cycles of induction study intervention, followed by repeat imaging studies (same modality as screening) within ≤4 weeks (21 days +/- 7 days) after C3D21 to exclude disease progression. mpMRI/contrast-enhanced or CT scan will assess local invasion by T3 disease or higher and the radiological response to treatment.
Participants who remain radiographically free of distant metastases and PR/SD/CR RECIST v1.1 will proceed to TURBT within 6 weeks of the last dose of SG. TURBT will enable histopathological re-staging and will evaluate pathological response to treatment. The inclusion of bladder muscle in the resection specimen is required. Cystoscopy will be performed before TURBT, as indicated in the Schedule of Activities.
Patients with no evidence of disease at the cystoscopy, will undergo bladder mapping in case of positive urine cytology. In case of negative urine cytology, patients will be considered in as complete respose, in case of no evidence of disease at radiological evaluation.
Participants with radiological progression to metastatic disease or locally advanced disease (from cT2 to cT4 or from N0 to N1), as assessed radiographically, at this time will be considered to have met the primary endpoint of EFS (ie, had an "event") and will not receive further therapy on study, but will transition into survival follow-up and will be treated as per clinical practice.
Participants with pathological downstaging and radiological complete or partial response will continue to receive zimberelimab for 13 cycles (16 cycles as a total) to complete approximately 1 year of total therapy.
Non-responder patients who will maintain radiological or pathological stability will choose to undergo RC or RT/CT or to continue Zimberelimab for 1 years. Additional TURBT could be performed in order to achieve local control, according to the centre clinical practice.
Response to study intervention will be assessed through TURBT and CT SCAN and/or MRI. Imaging should continue to be performed until an EFS event occurs or withdrawal of consent, whichever occurs first. If new anticancer therapy is initiated, this should be documented.
All subjects will be followed for OS every 3 months until death, lost to follow-up, or withdrawal of study consent. Additional survival follow-up may continue for up to 3-5 years from the time of this analysis. To evaluate metastasis free survival, subjects will be monitored by radiographic assessment and cystoscopy on an every-12-week schedule (±5 days). RECIST 1.1 criteria will be used for the assessment. Subjects will be evaluated at every SG + Zimberelimab dose administration plus two additional follow-up visits for safety within the first 100 days from the last dose of study therapy. Beyond 100 days from the last dose of study therapy, subjects will be followed for ongoing drug-related adverse events until resolved, return to baseline or deemed irreversible, or until lost to follow-up, or withdrawal of study consent.
To assess local recurrence, cystoscopy will be performed every 12 weeks (+/- 1 7 days). In case of local recurrence, patients could be managed with TURBT as per clinical practice, in case patients will still be unfit for cystectomy or refuse surgery.
Approximately 63 patients will be enrolled and assigned to study intervention. At screening, a tumor specimen from TURBT or biopsy done as early as 90 days prior to enrollment will be submitted for central pathology review. All participants will undergo baseline screening imaging (CT or MRI of the chest, abdomen, pelvis) for clinical staging.
Eligible participants will be allocated to study intervention which consist in SG + Zimberelimab for 3 cycles followed by Zimberelimab for 13 cycles in patients who achieve CR/PR/SD at tumor evaluation.
The planned total duration of treatment is approximately 1 year, 3 cycles of SG and 16 cycles of Zimberelimab.
Treatment will be discontinued if the participant experiences unacceptable AE(s), intercurrent illness that prevents further administration of treatment, the investigator's decision to withdraw the participant, the participant withdraws consent, pregnancy of the participant, noncompliance with study intervention or procedure requirements, or the maximum number of cycles has been received for each treatment component individually.
Participants will complete 3 cycles of induction study intervention, followed by repeat imaging studies (same modality as screening) within ≤4 weeks (21 days +/- 7 days) after C3D21 to exclude disease progression. mpMRI/contrast-enhanced or CT scan will assess local invasion by T3 disease or higher and the radiological response to treatment.
Participants who remain radiographically free of distant metastases and PR/SD/CR RECIST v1.1 will proceed to TURBT within 6 weeks of the last dose of SG. TURBT will enable histopathological re-staging and will evaluate pathological response to treatment. The inclusion of bladder muscle in the resection specimen is required. Cystoscopy will be performed before TURBT, as indicated in the Schedule of Activities.
Patients with no evidence of disease at the cystoscopy, will undergo bladder mapping in case of positive urine cytology. In case of negative urine cytology, patients will be considered in as complete respose, in case of no evidence of disease at radiological evaluation.
Participants with radiological progression to metastatic disease or locally advanced disease (from cT2 to cT4 or from N0 to N1), as assessed radiographically, at this time will be considered to have met the primary endpoint of EFS (ie, had an "event") and will not receive further therapy on study, but will transition into survival follow-up and will be treated as per clinical practice.
Participants with pathological downstaging and radiological complete or partial response will continue to receive zimberelimab for 13 cycles (16 cycles as a total) to complete approximately 1 year of total therapy.
Non-responder patients who will maintain radiological or pathological stability will choose to undergo RC or RT/CT or to continue Zimberelimab for 1 years. Additional TURBT could be performed in order to achieve local control, according to the centre clinical practice.
Response to study intervention will be assessed through TURBT and CT SCAN and/or MRI. Imaging should continue to be performed until an EFS event occurs or withdrawal of consent, whichever occurs first. If new anticancer therapy is initiated, this should be documented.
All subjects will be followed for OS every 3 months until death, lost to follow-up, or withdrawal of study consent. Additional survival follow-up may continue for up to 3-5 years from the time of this analysis. To evaluate metastasis free survival, subjects will be monitored by radiographic assessment and cystoscopy on an every-12-week schedule (±5 days). RECIST 1.1 criteria will be used for the assessment. Subjects will be evaluated at every SG + Zimberelimab dose administration plus two additional follow-up visits for safety within the first 100 days from the last dose of study therapy. Beyond 100 days from the last dose of study therapy, subjects will be followed for ongoing drug-related adverse events until resolved, return to baseline or deemed irreversible, or until lost to follow-up, or withdrawal of study consent.
To assess local recurrence, cystoscopy will be performed every 12 weeks (+/- 1 7 days). In case of local recurrence, patients could be managed with TURBT as per clinical practice, in case patients will still be unfit for cystectomy or refuse surgery.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Bladder Cancer
Bladder Urothelial Carcinoma
Bladder Neoplasm
Muscle-Invasive Bladder Carcinoma
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sacituzumab Govitecan + Zimberelimab
patients will be treated with Sacituzumab Govitecan 1,8q21 plus + Zimberelimab q21 for 3 cycles then radiological imaging and TURB will be repeated and patients with Stability of disease or down staging will continue Zimberelimab until disease progression, or unacceptable toxicities or completion of treatment (16 cycles). Patients with progressive disease after 3 cycles of study intervention will be treated as per clinical practice.
Group Type
EXPERIMENTAL
Sacituzumab Govitecan + Zimberelimab
Intervention Type
DRUG
Sacituzumab Govitecan 7.5 mg/kg IV for 3 cycles Zimberelimab 360 mg IV for 16 cycles
Patients will be treated with Sacituzumab Govitecan 1,8q21 plus + Zimberelimab q21 for 3 cycles then radiological imaging and TURB will be repeated and patients with Stability of disease or down staging will continue Zimberelimab until disease progression, or unacceptable toxicities or completion of treatment (16 cycles). Patients with progressive disease after 3 cycles of study intervention will be treated as per clinical practice.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sacituzumab Govitecan + Zimberelimab
Sacituzumab Govitecan 7.5 mg/kg IV for 3 cycles Zimberelimab 360 mg IV for 16 cycles
Patients will be treated with Sacituzumab Govitecan 1,8q21 plus + Zimberelimab q21 for 3 cycles then radiological imaging and TURB will be repeated and patients with Stability of disease or down staging will continue Zimberelimab until disease progression, or unacceptable toxicities or completion of treatment (16 cycles). Patients with progressive disease after 3 cycles of study intervention will be treated as per clinical practice.
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
TRODELVY
AB122
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant is at least 18 years old of age, at the time of providing informed consent.
* The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.
* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2. Evaluation of ECOG is to be performed within 7 days prior to the first dose of study intervention.
* Patients deemed ineligible for Radical Cystectomy (RC) + Retroperitoneal lymphnode dissection (RPNLD) by a urologist and/or oncologist and/or anesthesiology.
* Cisplatin unfit patients as per Galsky criteria (ECOG Performance Status of 2 and/or creatinine-clearance \< 60 ml/min and/or CTCAE Gr ≥ 2 hearing loss and/or CTCAE Gr ≥ 2 neuropathy).
* Cisplatin-fit patients are admitted if they are unwilling to undergo Radical Cystectomy (RC) and unwilling for cisplatin-based chemotherapy.
* Patients deemed eligible for surgery will be included if they will be unwilling to undergo RC and will be ineligible and/or unwilling to cisplatin-based chemotherapy.
* cT2-cT4 bladder cancer patients with predominant urothelial histology or Squamous cell histologic variant with histological confirmed diagnosis of muscle-invasive bladder cancer (MIBC) obtained via a diagnostic or maximal TURBT performed within 90 days before enrollment.
* cN0-1 bladder cancer patients with predominant urothelial histology or Squamous cell histologic variant
* Have adequate organ function as defined as follow (Specimens must be collected within 10 days prior to the start of study intervention):
* Adequate hematologic counts without transfusional or growth factor support within 2 weeks of study treatment initiations (hemoglobin ≥ 9 g/dL, ANC ≥ 1500/mm3, and platelets ≥ 100,000/μL).
* Adequate hepatic function (bilirubin ≤ 1.5 × ULN, AST and ALT ≤ 2.5 × ULN or ≤ 5 × ULN if known liver metastases, and serum albumin \> 3 g/dL).
* Creatinine clearance ≥ 30 mL/min as assessed by the Cockcroft-Gault equation.
* International normalized ratio (INR)/PT and PTT or aPTT ≤ 1.5 ULN unless patient is currently receiving therapeutic anticoagulant therapy.
* Patients with HIV must be on antiretroviral therapy (ART) and have a well-controlled
HIV infection/disease defined as:
* Patients on ART must have a CD4+ T-cell count ≥ 350 cells/mm3 at time of screening.
* Patients on ART must have achieved and maintained virologic suppression defined as confirmed HIV RNA level below 50 copies/mL or the lower limit of qualification (below the limit of detection) using the locally available assay at the time of screening and for at least 12 weeks prior to screening.
* Patients on ART must have been on a stable regimen, without changes in drugs or dose modification, for at least 4 weeks prior to study entry (Day 1).
* The combination ART regimen must not contain any medications that may interfere with SN-38 metabolism.
* The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.
* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2. Evaluation of ECOG is to be performed within 7 days prior to the first dose of study intervention.
* Patients deemed ineligible for Radical Cystectomy (RC) + Retroperitoneal lymphnode dissection (RPNLD) by a urologist and/or oncologist and/or anesthesiology.
* Cisplatin unfit patients as per Galsky criteria (ECOG Performance Status of 2 and/or creatinine-clearance \< 60 ml/min and/or CTCAE Gr ≥ 2 hearing loss and/or CTCAE Gr ≥ 2 neuropathy).
* Cisplatin-fit patients are admitted if they are unwilling to undergo Radical Cystectomy (RC) and unwilling for cisplatin-based chemotherapy.
* Patients deemed eligible for surgery will be included if they will be unwilling to undergo RC and will be ineligible and/or unwilling to cisplatin-based chemotherapy.
* cT2-cT4 bladder cancer patients with predominant urothelial histology or Squamous cell histologic variant with histological confirmed diagnosis of muscle-invasive bladder cancer (MIBC) obtained via a diagnostic or maximal TURBT performed within 90 days before enrollment.
* cN0-1 bladder cancer patients with predominant urothelial histology or Squamous cell histologic variant
* Have adequate organ function as defined as follow (Specimens must be collected within 10 days prior to the start of study intervention):
* Adequate hematologic counts without transfusional or growth factor support within 2 weeks of study treatment initiations (hemoglobin ≥ 9 g/dL, ANC ≥ 1500/mm3, and platelets ≥ 100,000/μL).
* Adequate hepatic function (bilirubin ≤ 1.5 × ULN, AST and ALT ≤ 2.5 × ULN or ≤ 5 × ULN if known liver metastases, and serum albumin \> 3 g/dL).
* Creatinine clearance ≥ 30 mL/min as assessed by the Cockcroft-Gault equation.
* International normalized ratio (INR)/PT and PTT or aPTT ≤ 1.5 ULN unless patient is currently receiving therapeutic anticoagulant therapy.
* Patients with HIV must be on antiretroviral therapy (ART) and have a well-controlled
HIV infection/disease defined as:
* Patients on ART must have a CD4+ T-cell count ≥ 350 cells/mm3 at time of screening.
* Patients on ART must have achieved and maintained virologic suppression defined as confirmed HIV RNA level below 50 copies/mL or the lower limit of qualification (below the limit of detection) using the locally available assay at the time of screening and for at least 12 weeks prior to screening.
* Patients on ART must have been on a stable regimen, without changes in drugs or dose modification, for at least 4 weeks prior to study entry (Day 1).
* The combination ART regimen must not contain any medications that may interfere with SN-38 metabolism.
Exclusion Criteria
1. Positive serum pregnancy test (Appendices 9.4) or women who are breastfeeding.
2. Known hypersensitivity to the study drug, its metabolites, or formulation excipient.
3. Requirement for ongoing therapy with or prior use of any prohibited medications listed in Section.
4. Have had a prior anticancer biologic agent within 4 weeks prior to enrollment or have had prior chemotherapy or targeted small molecule therapy. Patients participating in observational studies are eligible.
5. Have previously received topoisomerase 1 inhibitors.
6. Have an active second malignancy. Note: patients with a history of malignancy that have been completely treated, with no evidence of active cancer for 3 years prior to enrollment, or patients with surgically cured tumors with low risk of recurrence (eg, nonmelanoma skin cancer, histologically confirmed complete excision of carcinoma in situ, or similar) are allowed to enroll. Other exception are localized prostate cancer with a Gleason score of 6 (treated within the last 24 months or untreated and under surveillance) and localized prostate cancer with a Gleason score of 3+4 that has been treated more than 6 months prior to full study screening and considered to have a very low risk of recurrence.
7. Patients with neuroendocrine histology will be excluded.
8. Have active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or GI perforation within 6 months of enrollment.
9. Have active serious infection requiring antibiotics.
10. Have known history of HIV-1 or 2 (or positive HIV-1/2 antibody, if done at screening) with detectable viral load OR taking medications that may interfere with SN-38 metabolism.
11. Have active hepatitis B virus (HBV) or hepatitis C virus (HCV). In patients with a history of HBV or HCV, patients with detectable viral loads will be excluded.
* Patients who test positive for hepatitis B surface antigen (HBsAg). Patients who test positive for hepatitis B core antibody (anti-HBc) will require HBV DNA by quantitative polymerase chain reaction (PCR) for confirmation of active disease.
* Patients who test positive for HCV antibody. Patients who test positive for HCV antibody will require HCV RNA by quantitative PCR for confirmation of active disease. Patients with a known history of HCV or a positive HCV antibody test will not require a HCV antibody at screening and will only require HCV RNA by quantitative PCR for confirmation of active disease.
12. Have other concurrent medical or psychiatric conditions that, in the investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.
13. Any medical condition that, in the investigator's or sponsor's opinion, poses an undue risk to the patient's participation in the study.
14. Use of other investigational drugs (drugs not marketed for any indication) within 28 days or 5 half-lives (whichever is longer) of first dose of study drug.
2. Known hypersensitivity to the study drug, its metabolites, or formulation excipient.
3. Requirement for ongoing therapy with or prior use of any prohibited medications listed in Section.
4. Have had a prior anticancer biologic agent within 4 weeks prior to enrollment or have had prior chemotherapy or targeted small molecule therapy. Patients participating in observational studies are eligible.
5. Have previously received topoisomerase 1 inhibitors.
6. Have an active second malignancy. Note: patients with a history of malignancy that have been completely treated, with no evidence of active cancer for 3 years prior to enrollment, or patients with surgically cured tumors with low risk of recurrence (eg, nonmelanoma skin cancer, histologically confirmed complete excision of carcinoma in situ, or similar) are allowed to enroll. Other exception are localized prostate cancer with a Gleason score of 6 (treated within the last 24 months or untreated and under surveillance) and localized prostate cancer with a Gleason score of 3+4 that has been treated more than 6 months prior to full study screening and considered to have a very low risk of recurrence.
7. Patients with neuroendocrine histology will be excluded.
8. Have active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or GI perforation within 6 months of enrollment.
9. Have active serious infection requiring antibiotics.
10. Have known history of HIV-1 or 2 (or positive HIV-1/2 antibody, if done at screening) with detectable viral load OR taking medications that may interfere with SN-38 metabolism.
11. Have active hepatitis B virus (HBV) or hepatitis C virus (HCV). In patients with a history of HBV or HCV, patients with detectable viral loads will be excluded.
* Patients who test positive for hepatitis B surface antigen (HBsAg). Patients who test positive for hepatitis B core antibody (anti-HBc) will require HBV DNA by quantitative polymerase chain reaction (PCR) for confirmation of active disease.
* Patients who test positive for HCV antibody. Patients who test positive for HCV antibody will require HCV RNA by quantitative PCR for confirmation of active disease. Patients with a known history of HCV or a positive HCV antibody test will not require a HCV antibody at screening and will only require HCV RNA by quantitative PCR for confirmation of active disease.
12. Have other concurrent medical or psychiatric conditions that, in the investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.
13. Any medical condition that, in the investigator's or sponsor's opinion, poses an undue risk to the patient's participation in the study.
14. Use of other investigational drugs (drugs not marketed for any indication) within 28 days or 5 half-lives (whichever is longer) of first dose of study drug.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gilead Sciences
INDUSTRY
Sponsor Role
collaborator
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Giuseppe Procopio, MD
Role: PRINCIPAL_INVESTIGATOR
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fondazione Irccs Istituto Nazionale Dei Tumori Di Milano
Milan, , Italy
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Italy
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Bokarica P, Hrkac A, Gilja I. Re: J. Alfred Witjes, Thierry Lebret, Eva M. Comperat, et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur Urol 2017;71:462-75. Eur Urol. 2017 Aug;72(2):e45. doi: 10.1016/j.eururo.2017.02.031. Epub 2017 Mar 6. No abstract available.
Reference Type
BACKGROUND
Softness K, Kaul S, Fleishman A, Efstathiou J, Bellmunt J, Kim SP, Korets R, Chang P, Wagner A, Olumi AF, Gershman B. Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder. Urol Oncol. 2022 Jun;40(6):272.e1-272.e9. doi: 10.1016/j.urolonc.2021.12.015. Epub 2022 Jan 17.
Reference Type
BACKGROUND
Royce TJ, Feldman AS, Mossanen M, Yang JC, Shipley WU, Pandharipande PV, Efstathiou JA. Comparative Effectiveness of Bladder-preserving Tri-modality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer. Clin Genitourin Cancer. 2019 Feb;17(1):23-31.e3. doi: 10.1016/j.clgc.2018.09.023. Epub 2018 Oct 4.
Reference Type
BACKGROUND
Mitin T, Hunt D, Shipley WU, Kaufman DS, Uzzo R, Wu CL, Buyyounouski MK, Sandler H, Zietman AL. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. Lancet Oncol. 2013 Aug;14(9):863-72. doi: 10.1016/S1470-2045(13)70255-9. Epub 2013 Jul 1.
Reference Type
BACKGROUND
James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, Crundwell M, Sizer B, Sreenivasan T, Hendron C, Lewis R, Waters R, Huddart RA; BC2001 Investigators. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012 Apr 19;366(16):1477-88. doi: 10.1056/NEJMoa1106106.
Reference Type
BACKGROUND
Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulovic S, Demey W, Ullen A, Loriot Y, Sridhar SS, Tsuchiya N, Kopyltsov E, Sternberg CN, Bellmunt J, Aragon-Ching JB, Petrylak DP, Laliberte R, Wang J, Huang B, Davis C, Fowst C, Costa N, Blake-Haskins JA, di Pietro A, Grivas P. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2020 Sep 24;383(13):1218-1230. doi: 10.1056/NEJMoa2002788. Epub 2020 Sep 18.
Reference Type
BACKGROUND
Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, Necchi A, Valderrama BP, Ravaud A, Shariat SF, Szabados B, van der Heijden MS, Gillessen S; ESMO Guidelines Committee. Electronic address: [email protected]. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Mar;33(3):244-258. doi: 10.1016/j.annonc.2021.11.012. Epub 2021 Nov 30. No abstract available.
Reference Type
BACKGROUND
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.
Reference Type
BACKGROUND
Lin N, Zhang M, Bai H, Liu H, Cui J, Ke X, Zhang H, Liu L, Yan D, Jiang Y, Zang A, Qi J, Wang L, Liu Z, Xu B, Zhang Y, Zhang Z, Zhao X, Hu C, Yang S, Zhou H, Shi J, Shao Z, Xiang Y, Zhu J, Song Y, Zhu J. Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study. Eur J Cancer. 2022 Mar;164:117-126. doi: 10.1016/j.ejca.2021.07.021. Epub 2021 Aug 27.
Reference Type
BACKGROUND
Loriot Y, Petrylak DP, Rezazadeh Kalebasty A, Flechon A, Jain RK, Gupta S, Bupathi M, Beuzeboc P, Palmbos P, Balar AV, Kyriakopoulos CE, Pouessel D, Sternberg CN, Tonelli J, Sierecki M, Zhou H, Grivas P, Barthelemy P, Tagawa ST. TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes. Ann Oncol. 2024 Apr;35(4):392-401. doi: 10.1016/j.annonc.2024.01.002. Epub 2024 Jan 18.
Reference Type
BACKGROUND
Grivas P, Pouessel D, Park CH, Barthelemy P, Bupathi M, Petrylak DP, Agarwal N, Gupta S, Flechon A, Ramamurthy C, Davis NB, Recio-Boiles A, Sternberg CN, Bhatia A, Pichardo C, Sierecki M, Tonelli J, Zhou H, Tagawa ST, Loriot Y. Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3. J Clin Oncol. 2024 Apr 20;42(12):1415-1425. doi: 10.1200/JCO.22.02835. Epub 2024 Jan 23.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PreSAVE INT 2024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Intravesical Chemotherapy Treatment of Superficial Bladder Cancer
NCT00491114
COMPLETED
PHASE2
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence
NCT06682728
RECRUITING
PHASE2
Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer
NCT04909775
UNKNOWN
PHASE2
Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer
NCT05531123
RECRUITING
PHASE2
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
NCT06524544
RECRUITING
PHASE3
S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium
NCT00045630
COMPLETED
PHASE2
Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
NCT04527991
COMPLETED
PHASE3
Efficacy of Gemcitabine Submucosal Injection for Preventing Recurrence in Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer: A Randomized Trial
NCT07198451
NOT_YET_RECRUITING
PHASE2/PHASE3
Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
NCT04164082
ACTIVE_NOT_RECRUITING
PHASE2
Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer
NCT05401279
UNKNOWN
PHASE2
Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
NCT03532451
COMPLETED
PHASE1
Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder
NCT02845323
ACTIVE_NOT_RECRUITING
PHASE2
Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery
NCT02944357
WITHDRAWN
NA
Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk.
NCT00191711
COMPLETED
PHASE2
An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma
NCT04586244
TERMINATED
PHASE2
Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
NCT06161532
RECRUITING
PHASE2
Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer
NCT05241340
ACTIVE_NOT_RECRUITING
PHASE2
A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
NCT04165317
ACTIVE_NOT_RECRUITING
PHASE3
Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer
NCT06059547
ACTIVE_NOT_RECRUITING
PHASE2
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
NCT00234039
COMPLETED
PHASE2
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
NCT03661320
ACTIVE_NOT_RECRUITING
PHASE3
Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients
NCT04863885
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer
NCT06829823
NOT_YET_RECRUITING
PHASE2
A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
NCT04688931
TERMINATED
PHASE3
Comprehensive Bladder Preservation Therapy on Patients With Muscle Invasive Bladder Cancer
NCT05445648
NOT_YET_RECRUITING
PHASE2